China Diabetes Cardiovascular Initiative (CDCV)

August 31, 2021 updated by: Dong ZHAO, Beijing Institute of Heart, Lung and Blood Vessel Diseases
As a collaborative project between American Heart Association, Chinese Society of Cardiology, American Diabetes Association and Chinese Diabetes Society, the China Diabetes Cardiovascular Initiative aims to enhance the attention and awareness of cardiovascular health care professionals (HCPs) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

9600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized with acute coronary syndrome and diabetes from 40 tertiary hospitals from China.

Description

Inclusion Criteria:

  1. Patients hospitalized with acute coronary syndrome and diabetes.
  2. Aged at least 18 years.

Exclusion Criteria:

None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of STEMI patients receiving reperfusion therapy by PCI
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival)
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of NSTE-ACS patients receiving risk stratification at admission
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients prescribed dual antiplatelet medications at discharge
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients with indications prescribed a beta-blocker at discharge
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients prescribed a statin at discharge
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients with indications prescribed an ACE-I or ARB at discharge
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients that receiving an LDL-C assessment
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients with evaluation for LV systolic function by echocardiography
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of smoking patients that receiving smoking cessation advice/counseling
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving fasting glucose test at least twice
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving HbA1C test
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients with body height and weight measured and documented
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving guidance on individualized dietary
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving guidance on individualized physical activity
Time Frame: Duration of hospital stay, an expected average of 1 week
Duration of hospital stay, an expected average of 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

September 1, 2021

Primary Completion (ANTICIPATED)

December 31, 2023

Study Completion (ANTICIPATED)

December 31, 2023

Study Registration Dates

First Submitted

August 31, 2021

First Submitted That Met QC Criteria

August 31, 2021

First Posted (ACTUAL)

September 8, 2021

Study Record Updates

Last Update Posted (ACTUAL)

September 8, 2021

Last Update Submitted That Met QC Criteria

August 31, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CDCV2021

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Clinical Trials on Quality improvement activities

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe